AR070655A1 - Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas - Google Patents

Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas

Info

Publication number
AR070655A1
AR070655A1 ARP080104293A ARP080104293A AR070655A1 AR 070655 A1 AR070655 A1 AR 070655A1 AR P080104293 A ARP080104293 A AR P080104293A AR P080104293 A ARP080104293 A AR P080104293A AR 070655 A1 AR070655 A1 AR 070655A1
Authority
AR
Argentina
Prior art keywords
group
optionally substituted
alkyl
aryl
halogen atom
Prior art date
Application number
ARP080104293A
Other languages
English (en)
Spanish (es)
Inventor
Gilbert Marciniak
Nicolas Muzet
Annie Clauss
Christophe Glaess
Andre Seyer
Bertrand Vivet
Jean-Francois Nave
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR070655A1 publication Critical patent/AR070655A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ARP080104293A 2007-10-03 2008-10-01 Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas AR070655A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706931A FR2921926B1 (fr) 2007-10-03 2007-10-03 Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.

Publications (1)

Publication Number Publication Date
AR070655A1 true AR070655A1 (es) 2010-04-28

Family

ID=39470387

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104293A AR070655A1 (es) 2007-10-03 2008-10-01 Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas

Country Status (40)

Country Link
US (1) US8242126B2 (cg-RX-API-DMAC7.html)
EP (1) EP2205593B1 (cg-RX-API-DMAC7.html)
JP (1) JP5411143B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100082345A (cg-RX-API-DMAC7.html)
CN (1) CN101842368B (cg-RX-API-DMAC7.html)
AR (1) AR070655A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008337382B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0818690A2 (cg-RX-API-DMAC7.html)
CA (1) CA2701150C (cg-RX-API-DMAC7.html)
CL (1) CL2008002946A1 (cg-RX-API-DMAC7.html)
CO (1) CO6270227A2 (cg-RX-API-DMAC7.html)
CR (1) CR11327A (cg-RX-API-DMAC7.html)
CY (1) CY1117461T1 (cg-RX-API-DMAC7.html)
DK (1) DK2205593T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2010000089A (cg-RX-API-DMAC7.html)
EA (1) EA018766B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010058A (cg-RX-API-DMAC7.html)
ES (1) ES2567567T3 (cg-RX-API-DMAC7.html)
FR (1) FR2921926B1 (cg-RX-API-DMAC7.html)
GT (1) GT201000069A (cg-RX-API-DMAC7.html)
HN (1) HN2010000572A (cg-RX-API-DMAC7.html)
HR (1) HRP20160359T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028770T2 (cg-RX-API-DMAC7.html)
IL (1) IL204814A0 (cg-RX-API-DMAC7.html)
MA (1) MA31832B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010003495A (cg-RX-API-DMAC7.html)
MY (1) MY153763A (cg-RX-API-DMAC7.html)
NI (1) NI201000039A (cg-RX-API-DMAC7.html)
NZ (1) NZ584430A (cg-RX-API-DMAC7.html)
PA (1) PA8797701A1 (cg-RX-API-DMAC7.html)
PE (1) PE20090960A1 (cg-RX-API-DMAC7.html)
PL (1) PL2205593T3 (cg-RX-API-DMAC7.html)
SI (1) SI2205593T1 (cg-RX-API-DMAC7.html)
SV (1) SV2010003514A (cg-RX-API-DMAC7.html)
TN (1) TN2010000130A1 (cg-RX-API-DMAC7.html)
TW (1) TWI421076B (cg-RX-API-DMAC7.html)
UA (1) UA99485C2 (cg-RX-API-DMAC7.html)
UY (1) UY31376A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009077680A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201002307B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8107260B2 (en) * 2007-11-15 2012-01-31 Illinois Tool Works Inc. EMI shielding and environmental seal device
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944206B1 (fr) * 2009-04-09 2012-12-28 Sanofi Aventis Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
KR101116234B1 (ko) * 2009-10-29 2014-03-06 (주)퓨쳐켐 (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
WO2011150457A2 (en) * 2010-06-01 2011-12-08 The University Of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
TW201348213A (zh) * 2012-04-24 2013-12-01 Chugai Pharmaceutical Co Ltd 喹唑啉二酮衍生物
TW201348187A (zh) 2012-04-24 2013-12-01 Chugai Pharmaceutical Co Ltd 苯甲醯胺衍生物
EP2854780B1 (en) 2012-06-05 2017-08-30 University Of Kansas Inhibitors of respiratory syncytial virus
WO2015003879A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicylic derivatives
JP6307088B2 (ja) 2013-10-23 2018-04-04 中外製薬株式会社 キナゾリノンおよびイソキノリノン誘導体
CZ2015601A3 (cs) * 2015-09-02 2017-03-15 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
CN107267455A (zh) * 2017-08-23 2017-10-20 安徽惠恩生物科技股份有限公司 一种嵌合抗原受体nk细胞的制备方法
GB201918416D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
EP4572765A1 (en) 2022-08-18 2025-06-25 Mitodicure GmbH Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance
US12258345B1 (en) 2023-12-12 2025-03-25 King Faisal University Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
CA2218548A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited Xanthines and their therapeutic use
JP2002308774A (ja) * 2001-04-12 2002-10-23 Nippon Zoki Pharmaceut Co Ltd Iv型ホスホジエステラーゼ選択的阻害剤
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US20090111837A1 (en) 2005-03-01 2009-04-30 Peter Cox Use of pde7 inhibitors for the treatment of neuropathic pain
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
US7846664B2 (en) 2005-12-07 2010-12-07 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (CLL)

Also Published As

Publication number Publication date
UY31376A1 (es) 2009-05-29
PA8797701A1 (es) 2009-05-15
MX2010003495A (es) 2010-04-21
JP5411143B2 (ja) 2014-02-12
BRPI0818690A2 (pt) 2015-04-14
CA2701150A1 (fr) 2009-06-25
NI201000039A (es) 2010-08-13
MA31832B1 (fr) 2010-11-01
EA201070424A1 (ru) 2011-04-29
ZA201002307B (en) 2011-06-29
FR2921926B1 (fr) 2009-12-04
SV2010003514A (es) 2011-01-31
SI2205593T1 (sl) 2016-05-31
EP2205593B1 (fr) 2016-01-13
MY153763A (en) 2015-03-13
CL2008002946A1 (es) 2010-02-12
CO6270227A2 (es) 2011-04-20
ECSP10010058A (es) 2010-04-30
KR20100082345A (ko) 2010-07-16
PL2205593T3 (pl) 2016-09-30
CN101842368B (zh) 2014-03-12
EA018766B1 (ru) 2013-10-30
CN101842368A (zh) 2010-09-22
HRP20160359T1 (hr) 2016-05-06
TWI421076B (zh) 2014-01-01
DK2205593T3 (en) 2016-04-18
AU2008337382B2 (en) 2013-11-21
FR2921926A1 (fr) 2009-04-10
EP2205593A1 (fr) 2010-07-14
NZ584430A (en) 2011-11-25
IL204814A0 (en) 2010-11-30
GT201000069A (es) 2012-03-26
UA99485C2 (ru) 2012-08-27
US20100298298A1 (en) 2010-11-25
AU2008337382A1 (en) 2009-06-25
JP2010540602A (ja) 2010-12-24
CR11327A (es) 2010-09-13
CA2701150C (fr) 2016-08-16
TW200922591A (en) 2009-06-01
ES2567567T3 (es) 2016-04-25
DOP2010000089A (es) 2010-05-15
WO2009077680A1 (fr) 2009-06-25
PE20090960A1 (es) 2009-08-10
HN2010000572A (es) 2013-03-11
CY1117461T1 (el) 2017-04-26
TN2010000130A1 (fr) 2011-09-26
US8242126B2 (en) 2012-08-14
HUE028770T2 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
AR070655A1 (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
ES2647163T3 (es) Derivados de isoquinolinona sustituidos con una purina útiles como inhibidores de la PI3K
CO6150145A2 (es) Derivados de aril/heterociclo/cicloalquil/cicloalquil fenil substituidos utiles como agentes inmunosupresores
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR082885A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
AR077598A1 (es) Compuestos heterociclicos fusionados como modulares de canales ionicos
AR051093A1 (es) Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR064517A1 (es) Pirimidinionas biciclicas y sus usos
AR076232A1 (es) Aplicaciones en terapeutica de derivados de quinazolinadiona.
AR079250A1 (es) Derivados de pirazolo[1,5-a]piridina utiles en el tratamiento de enfermedades del snc y canceres, composiciones farmaceuticas que los contienen e intermediario de sintesis.
AR087771A1 (es) Moduladores de la pde10
AR050186A1 (es) Derivados de amino-piperidina, su preparacion y su aplicacion en terapeutica.
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
AR082004A1 (es) Compuestos de fusion de piridina
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR083694A1 (es) USO DE COMPUESTOS FARMACEUTICOS ACTIVOS PARA EL TRATAMIENTO DE ESTADOS PATOLOGICOS DEL SISTEMA NERVIOSO CENTRAL, COMPOSICION FARMACEUTICA, MODULADOR ALOSTERICO NEGATIVO DEL GABA A a5, METODO
AR053109A1 (es) DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2.
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR077365A1 (es) Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure